Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Dabigatran Excess: Case Report and Review of the Literature

Dabigatran Excess: Case Report and Review of the Literature Cardiol Ther (2013) 2:111–124 DOI 10.1007/s40119-013-0016-1 CASE REPORT Dabigatran Excess: Case Report and Review of the Literature • • • Amy Sarma Jeffrey E. Rossi Jean M. Connors Robert P. Giugliano To view enhanced content go to www.cardiologytherapy-open.com Received: April 3, 2013 / Published online: June 1, 2013 The Author(s) 2013. This article is published with open access at Springerlink.com of anticoagulation and absence of an antidote ABSTRACT or established therapies to reverse the Introduction: Novel oral anticoagulants are anticoagulant effect make management of increasingly used for stroke prophylaxis in cases of over-anticoagulation challenging. patients with non-valvular atrial fibrillation. Case Report: In this case report an 87-year-old While these agents offer a more predictable man with a history of atrial fibrillation pharmacokinetic profile, the lack of readily presented with dabigatran excess in the setting available laboratory tests to monitor the level of life-threatening, acute renal and hepatic failure. The authors review the use of A. Sarma and J. E. Rossi contributed equally to the writing of this paper. dabigatran in elderly patients, the available data on management of patients with excess A. Sarma  J. E. Rossi  J. M. Connors anticoagulation, and the potential options for R. P. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Dabigatran Excess: Case Report and Review of the Literature

Download PDF
14 pages

Loading next page...
 
/lp/springer-journals/dabigatran-excess-case-report-and-review-of-the-literature-5b4dQZsMd3
Publisher
Springer Journals
Copyright
Copyright © 2013 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Cardiology
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-013-0016-1
pmid
25135294
Publisher site
See Article on Publisher Site

Abstract

Cardiol Ther (2013) 2:111–124 DOI 10.1007/s40119-013-0016-1 CASE REPORT Dabigatran Excess: Case Report and Review of the Literature • • • Amy Sarma Jeffrey E. Rossi Jean M. Connors Robert P. Giugliano To view enhanced content go to www.cardiologytherapy-open.com Received: April 3, 2013 / Published online: June 1, 2013 The Author(s) 2013. This article is published with open access at Springerlink.com of anticoagulation and absence of an antidote ABSTRACT or established therapies to reverse the Introduction: Novel oral anticoagulants are anticoagulant effect make management of increasingly used for stroke prophylaxis in cases of over-anticoagulation challenging. patients with non-valvular atrial fibrillation. Case Report: In this case report an 87-year-old While these agents offer a more predictable man with a history of atrial fibrillation pharmacokinetic profile, the lack of readily presented with dabigatran excess in the setting available laboratory tests to monitor the level of life-threatening, acute renal and hepatic failure. The authors review the use of A. Sarma and J. E. Rossi contributed equally to the writing of this paper. dabigatran in elderly patients, the available data on management of patients with excess A. Sarma  J. E. Rossi  J. M. Connors anticoagulation, and the potential options for R. P.

Journal

Cardiology and Therapy – Springer Journals

Published: Jun 1, 2013

References

  • Dabigatran versus warfarin in patients with atrial fibrillation
    Connolly, SJ; Ezekowitz, MD; Yusuf, S
  • Dabigatran and postmarketing reports of bleeding
    Southworth, MR; Reichman, ME; Unger, EF
  • Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Ryn, J; Stangier, J; Haertter, S
  • Effects on routine coagulation screens and assessment of anticoagulation intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British committee for standards in haematology
    Baglin, T; Keeling, D; Kitchen, S
  • Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant
    Ganetsky, M; Babu, KM; Salhanick, SD; Brown, RS; Boyer, EW
  • Periprocedural management and approach to bleeding in patients taking dabigatran
    Weitz, JI; Quinlan, DJ; Eikelboom, JW
  • Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin
    Eisert, WG; Hauel, N; Stangier, J; Wienen, W; Clemens, A; Ryn, J
  • Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study
    Dager, WE; Gosselin, RC; Kitchen, S; Dwyer, D
  • Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients
    Bene, J; Said, W; Rannou, M; Deheul, S; Coupe, P; Gautier, S
  • The use of dabigatran in elderly patients
    Legrand, M; Mateo, J; Aribaud, A
  • Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment
    Wychowski, MK; Kouides, PA
  • Fatal dabigatran toxicity secondary to acute renal failure
    Maddry, JK; Amir, MK; Sessions, D; Heard, K
  • Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency
    Fellows, SE; Rosini, JM; Curtis, JA; Volz, EG
  • Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation
    Louet, L-L; Wolf, M; Soufir, L
  • Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA)
    Pengo, V; Crippa, L; Falanga, A
  • Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial
    Eikelboom, JW; Wallentin, L; Connolly, SJ
  • Drug and dietary interactions of the new and emerging oral anticoagulants
    Walenga, JM; Adiguzel, C
  • Management of dabigatran-inducted anticoagulation in trauma and acute care surgery patients
    Obeng-Gyasi, S; Loor, MM; Samotowka, MA; Moorman, ML
  • Acute management of bleeding in patients on novel oral anticoagulants
    Siegal, DM; Crowther, MA
  • Recombination factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding
    Warkentin, TE; Margetts, P; Connolly, SJ; Lamy, A; Ricci, C; Eikelboom, JW
  • 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines
    Wann, LS; Curtis, AB; Ellenbogen, KA
  • Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers
    Wolzt, M; Levi, M; Sarich, TC
  • The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine
    Davis, PK; Musunuru, H; Walsh, H; Mitra, R; Ploplis, V; Castellino, FJ
  • Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
    Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; Meijers, JC; Buller, HR; Levi, M
  • Emergency management of bleeding associated with old and new oral anticoagulants
    Peacock, WF; Gearhart, MM; Mills, RM
  • Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomized crossover ex vivo study in healthy volunteers
    Marlu, R; Hodaj, E; Paris, A; Albaladejo, P; Cracowski, JL; Pernod, G
  • Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models
    Ryn, J; Litzenburger, T; Waterman, A
  • Antidotes edge closer to reversing effects of new blood thinners
    Dolgin, E
  • Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors
    Lu, G; Luan, P; Hollenbach, SJ
  • A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
    Lu, G; Deguzman, FR; Hollenbach, SJ
  • PRT064445 but not recombinant Fviia reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model
    Hollenbach, SJ; Genmin, L; Siusze, T; Lee, G; Athiwat, H; Inagaki, M; Sinha, U
  • Safe use of hemodialysis for dabigatran removal before cardiac surgery
    Wanek, MR; Horn, ET; Elapavaluru, S; Baroody, SC; Sokos, G
  • Removal of dabigatran by hemodialysis
    Chang, DN; Dager, WE; Chin, AI
  • Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran
    Schulman, S; Wahlander, K; Lundstrom, T; Clason, SB; Eriksson, H
  • Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial
    Albers, GW; Diener, HC; Frison, L
  • Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial
    Wallentin, L; Wilcox, RG; Weaver, WD
  • A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial
    Eriksson, BI; Dahl, OE; Buller, HR